Skip to main content

Week In Review: InvoX, A Sino Biopharma Company, To Pay $161 Million To Acquire F-Star

InvoX Pharma, a Sino Biopharma subsidiary, will pay $161 million to acquire F-Star, a clinical stage company developing bispecific drugs for immunotherapies. Meanwhile, Reistone Biopharma completed a Series A financing of nearly $100 million.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.